The Meningitis Vaccine Project - contributing partners
Strategic input and collaboration on surveillance, epidemic control, socio-economic studies, and vaccine introduction
Agence de Médecine Préventive
The Agence de Médecine Préventive (AMP) is a France-based nonprofit organization contributing to the implementation of quality health services equivalent to those of the North for the benefit of people and especially children in the South. AMP undertook the original research and wrote the socio-economic study that provided the basis for the meningitis investment case that was submitted to the GAVI Alliance.
The GAVI Alliance is a Geneva-based public-private global health partnership committed to saving children's lives and protecting people's health by increasing access to immunisation in poor countries. fGAVI brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry in both industrialized and developing countries, research and technical agencies, civil society, the Bill & Melinda Gates Foundation and other private philanthropists. GAVI support consists of providing life-saving vaccines and strengthening health systems. Since its creation in 2000, 257 million children have been vaccinated and 5.4 million premature deaths averted thanks to GAVI-funded programmes.
The GAVI Alliance has made a critical contribution to tackling the burden of disease in the so-called “meningitis belt”, spending US$ 29.5 million for the introduction of MenAfriVac in Burkina Faso, Mali, and Niger. This money covers vaccine purchase, planning, equipment, mass campaigns, training, and evaluation. The Alliance has also spent a further US$ 55 million to secure a stockpile of polysaccharide vaccines for reactive outbreak responses in other countries of the meningitis belt between 2009-2013.
International Coordinating Group (ICG) on Vaccine Provision for Epidemic Meningitis Control
The ICG —a partnership composed of WHO, UNICEF, the International Federation of Red Cross and Red Crescent Societies, and Médecins sans Frontières—is responsible for the management of a stockpile of adequate quantities of meningococcal polysaccharide and meningococcal A conjugate vaccine for outbreak response. Both types of vaccine are critical for a smooth transition from epidemic response strategies with polysaccharide vaccines to prevention with conjugate A vaccine, through mass vaccination campaigns and routine immunization. Until multivalent conjugate vaccines are available, the stockpile will also continue to include polysaccharide vaccines for response to non-serogroup A meningococcal meningitis outbreaks (C or W135).
London School of Hygiene and Tropical Medicine
The London School of Hygiene and Tropical Medicine is leading the global research effort to study how meningococcal meningitis is spread in Africa, and to document the impact of MenAfriVac on reducing disease transmission.
Médecins sans Frontières
Médecins Sans Frontières is an independent medical humanitarian organization that delivers emergency aid to people affected by armed conflict, epidemics, health-care exclusion and natural disasters. Every year, MSF intervenes in response to outbreaks in the meningitis belt—in 2009, MSF vaccinated more than seven million people against Meningitis A. Until now, the availability of polysaccharide vaccines alone to respond to emergencies, confined the organization's response to trying to slow and stop epidemics. But in December 2010, MSF will begin vaccinating approximately 1.6 million people between the ages of 1 and 29 with the new meningitis A conjugate vaccine in Mali and Niger, as part of a larger effort coordinated by the WHO Regional Office for Africa, in these two countries and Burkina Faso. The new vaccine’s greater and longer lasting protection is a game changer for MSF’s future outbreak response and prevention.
Spanish Agency for International Development Cooperation (AECID)
The AECID has provided a financial contribution for the coordination of efforts in support of the introduction of MenAfriVac.
UNICEF is on the ground in more than 150 countries and territories to help children survive and thrive, from early childhood through adolescence. The world’s largest provider of vaccines for developing countries, UNICEF supports child health and nutrition, good water and sanitation, quality basic education for all boys and girls, and the protection of children from violence, exploitation, and AIDS.
The new meningitis A conjugate vaccine is being procured and supplied by UNICEF. In addition, as with all immunization campaigns, UNICEF has been preparing the way by engaging in social mobilisation, and conducting advocacy and training for community workers, while ensuring the support of traditional and religious leaders. These campaigns help to ensure acceptance and higher rates of immunization.
United States Centers for Disease Prevention and Control
The United States Centers for Disease Control and Prevention (CDC) is the lead United States agency for protecting the health and safety of people both in the United States of America and abroad.
The CDC has been an active participant in sub-Saharan meningococcal epidemiologic and vaccine studies for the last 25 years. Its role in MVP was to develop and perform serological assays to evaluate immune antibody responses induced by the immunization of participants in the clinical studies of MenAfriVac.